How Is the HLA-B27 Gene Inherited?

HLA-B27 is inherited as a straightforward gene on chromosome 6, passed from parent to child with a roughly 50 percent chance whenever one parent carries it. Each person receives one copy of the HLA-B gene from their mother and one from their father, and a single copy of the B27 variant is enough to make someone “HLA-B27 positive.” But the inheritance pattern tells only part of the story, because carrying this gene is far from a guarantee of developing ankylosing spondylitis or any other associated condition.

The Fifty-Fifty Odds From One Carrier Parent

HLA-B27 sits within the major histocompatibility complex (MHC) on chromosome 6, a region densely packed with immune-related genes. You inherit one version of this chromosomal region from each parent. If one of your parents carries HLA-B27 and the other does not, each child has about a 50 percent chance of inheriting the B27-carrying chromosome. If both parents carry it, the odds shift: roughly 75 percent of children will have at least one copy, and about 25 percent will inherit two copies, one from each parent.

HLA genes are expressed codominantly, meaning both copies are active. A person with one B27 allele and one non-B27 allele will display both versions on the surface of their cells. This is different from the classic “dominant vs. recessive” framing people learn in school. You don’t need two copies for the gene to show up, but having two copies isn’t silently redundant either.

The region around HLA-B tends to be inherited in large blocks of DNA that travel together across generations, known as conserved extended haplotypes. Research mapping these blocks found that specific combinations of closely linked genes within the MHC form single genetic units sometimes spanning over 1.5 million base pairs.¹ This means that when you inherit HLA-B27, you typically inherit a chunk of neighboring immune genes along with it, which can influence how the gene behaves in your body.

Does It Matter Which Parent Passes It On?

For the gene itself, no. You get the same HLA-B27 molecule whether it came from your mother or your father. But when it comes to the risk of developing ankylosing spondylitis, the sex of the affected parent turns out to matter in a way researchers didn’t initially expect.

A study tracking families of patients with ankylosing spondylitis found that affected mothers passed the disease on to their children significantly more often than affected fathers did.² The numbers are striking: among women who developed ankylosing spondylitis at a young age, about 38 percent of their children also developed the disease, compared with roughly 8 percent of children whose fathers had early-onset disease.³ This maternal effect was strongest when the mother’s symptoms began before age 21. Children and siblings of female patients had nearly twice the odds of developing ankylosing spondylitis compared with relatives of male patients.

The reasons for this asymmetry aren’t fully nailed down. It could involve interactions between the mother’s immune environment during pregnancy and the developing fetus, or it could reflect additional genetic susceptibility factors that cluster in families where women develop the condition. Either way, from a practical counseling standpoint, the sex of the affected parent appears to influence how likely the next generation is to develop symptoms, even when the HLA-B27 gene itself is identical.

One Copy Versus Two

Most people who are HLA-B27 positive carry just one copy. But a small fraction inherit a copy from both parents, making them homozygous. Research going back decades has found that homozygous individuals appear more susceptible to ankylosing spondylitis. In one study of 58 B27-positive patients with ankylosing spondylitis, about 15.5 percent were apparent homozygotes, far exceeding the roughly 4 percent expected by chance.⁴ Multiple independent studies confirmed the same trend. Interestingly, while homozygotes were more likely to develop the disease in the first place, the clinical severity wasn’t dramatically different from heterozygotes, with one exception: homozygotes had more frequent involvement of peripheral joints beyond the spine.

This gene-dosage effect makes biological sense. Cells in a homozygous person present more B27 molecules on their surface because both gene copies are producing the same protein. More B27 on the cell surface could amplify whatever immune process links the molecule to inflammation.

Not All HLA-B27 Is the Same

HLA-B27 isn’t a single uniform gene. It’s a family of subtypes, each differing by small changes in their DNA sequence. Over 30 variants have been identified, and they are not interchangeable when it comes to disease risk.⁵ The ancestral subtype, B*27:05, is the most common worldwide and is strongly linked to ankylosing spondylitis. B*27:02 is the other major disease-associated subtype in people of European descent. In Asian populations, B*27:04 and B*27:07 are the predominant disease-associated variants.

Two subtypes stand out for the opposite reason. B*27:06, common in Southeast Asia, and B*27:09, found in Sardinia, appear to carry little to no risk for ankylosing spondylitis. The molecular differences between these “protective” and “pathogenic” subtypes are tiny, sometimes just a single amino acid swap, but they can alter how the molecule binds and presents peptides to the immune system. A large multi-population study mapping 17 different populations across continents confirmed these subtype distributions and noted that B*27:05 was especially dominant in circumpolar and subarctic groups, while B*27:02 was concentrated in Middle Eastern and North African populations.⁶

This subtype diversity means that inheriting “HLA-B27” is not a single event with a single meaning. Which version you inherit, shaped by your family’s geographic and ethnic ancestry, matters for your actual disease risk. Genetic analyses suggest that these subtypes arose from B*27:05 along distinct geographic lines through mechanisms including genetic drift, population bottlenecks, and admixture.⁷

Why Most Carriers Never Develop Disease

This is the single most important point for anyone who just found out they carry HLA-B27: roughly 5 to 10 percent of carriers ever develop ankylosing spondylitis. The gene is necessary for the classic form of the disease but nowhere near sufficient. HLA-B27 contributes an estimated 20 to 25 percent of the overall heritability of ankylosing spondylitis.⁸ The total heritability of the disease is estimated at about 80 percent, and 113 other genetic loci have been identified that collectively account for roughly another 10 percent of the genetic risk on top of HLA-B27’s contribution.²

The gap between “highly heritable” and “HLA-B27 accounts for a quarter of that” tells you there is a large genetic landscape beyond this one gene. Environmental triggers, the gut microbiome, infections, mechanical stress on the skeleton, and other immune system genes all appear to play roles. A positive HLA-B27 test without symptoms is not a diagnosis of anything and doesn’t predict that disease will follow.

Other Genes That Shape the Risk

Among the most important modifiers is ERAP1, a gene that codes for an enzyme responsible for trimming peptides before they are loaded onto HLA molecules for immune presentation. Research has shown that ERAP1 variants affect ankylosing spondylitis risk only in people who are HLA-B27 positive, a gene-gene interaction that strongly suggests the disease mechanism involves how B27 handles the peptides it presents.⁹ If you carry the “wrong” ERAP1 variant but lack HLA-B27, your risk doesn’t change. The two genes work in concert.

A large genomic study of the HLA region also identified other HLA-B alleles that independently nudge risk in one direction or the other after accounting for B27’s massive effect. HLA-B*07:02 and HLA-B*57:01 were protective, while B*51:01 and a handful of others modestly increased risk.¹⁰ HLA-B60 in combination with B27 has been reported to raise risk dramatically through epistatic interaction.¹¹ The picture that emerges is one where HLA-B27 is the largest single domino, but dozens of other genetic dominoes need to fall in the right pattern for disease to develop.

How B27 Behaves at the Molecular Level

HLA-B27 encodes a protein that sits on the surface of most cells in your body and presents small fragments of proteins (peptides) to immune cells. This is how your immune system monitors what’s happening inside cells and detects infections. What makes B27 unusual is that it has a distinctive peptide-binding groove and some quirky folding behavior.

The B27 heavy chain has a tendency to misfold and form homodimers, pairs of B27 molecules stuck together, inside the endoplasmic reticulum where proteins are assembled. Research using engineered single-chain versions of the molecule pinpointed the F pocket and antigen binding groove as the regions driving this unusual folding and dimerization.¹² These misfolded dimers can trigger stress responses inside the cell and activate inflammatory pathways, which may help explain the link to autoimmune-type diseases.

B27 is also unusually independent when it comes to loading peptides. Most HLA class I molecules require a helper protein called tapasin to efficiently grab peptides. HLA-B*27:05 can achieve high levels of surface expression and present viral peptides even without tapasin, giving it flexibility in the range of peptides it can display.¹³ This flexibility is a double-edged sword: it helps fight certain infections effectively but may also mean B27 presents self-peptides or unusual peptide fragments that trigger misdirected immune attacks.

HLA-B27 Frequency Across Populations

The prevalence of HLA-B27 varies enormously depending on ancestry and geography. Among Northern European and Scandinavian populations, around 8 to 10 percent of the general population carries it. In some Indigenous Arctic populations, that figure can exceed 25 percent. Among people of sub-Saharan African descent, it is far less common, around 2 to 4 percent. A massive study of over 5.3 million bone marrow donors in Brazil, a country with considerable ethnic mixing, found B27 prevalence ranging from about 2.9 percent in Black Brazilians to 4.9 percent in White Brazilians, with intermediate rates in mixed-race and Indigenous groups.¹⁴

These population differences matter for inheritance counseling. If you’re of Northern European descent and you carry HLA-B27, your partner is more likely to also carry it than if you’re part of a population where the gene is rare. Two carriers having children together raises the chance of homozygous offspring, which, as discussed above, comes with somewhat elevated disease risk.

How HLA-B27 Testing Works

When a doctor orders an HLA-B27 test, the lab typically uses one of two broad approaches. The older and still common method is flow cytometry, which uses antibodies to detect the B27 protein on the surface of white blood cells. It’s fast and relatively inexpensive, and across large studies it agrees with genetic methods about 99 percent of the time.¹⁵

The second approach uses DNA-based methods, including PCR and next-generation sequencing, to look directly at the gene itself. These methods can distinguish between subtypes, which flow cytometry generally cannot. In one comparison study, flow cytometry produced a group of indeterminate results where about 15 percent turned out to be false positives, carrying the look-alike allele HLA-B*07:02 instead of true B27.¹⁶ Next-generation sequencing was the only method able to distinguish between pathogenic and non-pathogenic B27 variants. Another study in a diverse Australian population found that a common SNP-based screening test had only about 79 percent sensitivity, missing a meaningful fraction of true positives.¹⁷

For most clinical purposes, a standard flow cytometry or PCR test is sufficient. Subtype-level testing is rarely needed in routine care, but it could become more relevant as understanding of which subtypes carry disease risk continues to sharpen.

Why Evolution Hasn’t Eliminated HLA-B27

If HLA-B27 predisposes people to a painful chronic disease, why hasn’t natural selection weeded it out? The answer almost certainly lies in its value against infections. HLA-B27 carriers appear to have an advantage in fighting certain viruses. The gene is associated with lower viral load and slower disease progression in HIV infection, and with better odds of spontaneously clearing hepatitis C virus.¹⁸ The protection against hepatitis C appears to work through an immunodominant CD8+ T-cell response directed at a specific viral target, though this benefit is limited to hepatitis C genotype 1 and doesn’t extend to other genotypes.¹⁹

The same aggressive peptide-presentation machinery that may accidentally trigger autoimmune inflammation also makes B27 a potent weapon against viruses. In evolutionary terms, a gene that helps you survive infectious diseases during your reproductive years easily outweighs a gene that causes back pain starting in your twenties or thirties. Ankylosing spondylitis is debilitating but rarely lethal, so the survival benefit against infections likely kept B27 at substantial frequencies in many populations. Analysis of MHC class I genes across humans, chimpanzees, and gorillas confirms that these alleles have deep evolutionary roots, with lineages predating the split between these species.²⁰

Epigenetic Changes Linked to HLA-B27

Inheritance isn’t only about the DNA sequence itself. A genome-wide study of DNA methylation in ankylosing spondylitis found that carrying HLA-B*27 was associated with specific epigenetic changes, notably strong hypomethylation of a nearby gene called HCP5, as well as two other genes, TBCA and PLD6.²¹ One of the hypomethylated sites in HCP5 contains a genetic variant that is in tight linkage with HLA-B*27, meaning it controls methylation at that spot in an allele-specific way. This is a concrete example of how inheriting the B27 allele doesn’t just hand you a protein; it reshapes the epigenetic landscape of surrounding genes, potentially influencing immune function through mechanisms beyond the B27 molecule itself.

This area of research is still young, and it’s not yet clear how much of ankylosing spondylitis risk is mediated through these epigenetic effects versus the B27 protein directly. But it does mean that even among people who inherit the identical B27 subtype, differences in how the surrounding chromatin is regulated could contribute to why some develop disease and others don’t.

What Families of Carriers Should Know

Long-term family studies confirm that first-degree relatives of someone with ankylosing spondylitis face a substantially elevated lifetime risk of developing axial spondyloarthritis themselves, which has prompted calls for better patient education and family counseling.²² If you carry HLA-B27 and have a family member with ankylosing spondylitis, your risk is higher than a B27 carrier with no family history, because you presumably also share some of the additional risk genes.

For parents who carry HLA-B27 and wonder about their children: each child has a coin-flip chance of inheriting the gene. If your child does inherit it, the odds of developing full-blown ankylosing spondylitis are still modest, especially if the other parent has no family history of the condition. Beyond ankylosing spondylitis, HLA-B27 is linked to a wider cluster of conditions including acute anterior uveitis (eye inflammation), reactive arthritis, and inflammatory bowel disease-associated spondylitis.²³ These conditions share immune mechanisms but have their own distinct genetic modifiers, so inheriting HLA-B27 doesn’t put a person on a single predictable track. The practical takeaway for families is awareness without alarm: knowing a child carries HLA-B27 can prompt earlier evaluation if symptoms like chronic back stiffness or unexplained eye inflammation appear, but it doesn’t justify anxious surveillance of a healthy child.